» Articles » PMID: 35982247

The Intraocular Implant and Visual Rehabilitation Improve the Quality of Life of Elderly Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration

Overview
Specialty Ophthalmology
Date 2022 Aug 18
PMID 35982247
Authors
Affiliations
Soon will be listed here.
Abstract

Introduction: The objective of this prospective study was to evaluate the effects of intraocular macular lens implantation and visual rehabilitation on the quality of life of patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).

Methods: Patients with bilaterally decreased near vision (not better than 0.3 logMAR with the best correction), pseudophakia, were included in the project. The Scharioth macula lens (SML) was implanted into the patients' better-seeing eye. Intensive visual rehabilitation of the ability to perform nearby activities was performed for 20 consecutive postoperative days. All subjects were examined before and after SML implantation ophthalmologically. The National Eye Institute 25-Item Visual Function Questionnaire (NEI VFQ-25) was administered before and 6 months after surgery.

Results: Twenty eligible patients with mean age 81 years (63 to 92 years) were included in the project: 7 males and 13 females. Nineteen of them completed the 6-month follow-up. Near uncorrected visual acuity was 1.321 ± 0.208 logMAR before SML implantation and improved to 0.547 ± 0.210 logMAR after 6 months (dz =  - 2.846, p < 0.001, BF = 3.29E + 07). In the composite score of the NEI VFQ-25, there was an improvement in the general score and the specific domains related to the implantation. Participants reported fewer difficulties in performing near activities (dz = 0.91, p = 0.001, BF = 39.718) and upturns in mental health symptoms related to vision (dz = 0.62, p = .014, BF = 3.937).

Conclusion: SML implantation, followed by appropriate rehabilitation, improved near vision and increased the quality of life of visually handicapped patients with AMD in our project.

Citing Articles

Intraocular drug delivery systems for Diabetic retinopathy: Current and future prospective.

Taheri S, Poorirani S, Mostafavi S Bioimpacts. 2025; 15:30127.

PMID: 39963560 PMC: 11830143. DOI: 10.34172/bi.30127.


Advancements in the treatment of geographic atrophy: focus on pegcetacoplan in age-related macular degeneration.

Nadeem A, Malik I, Shariq F, Afridi E, Taha M, Raufi N Ann Med Surg (Lond). 2023; 85(12):6067-6077.

PMID: 38098608 PMC: 10718344. DOI: 10.1097/MS9.0000000000001466.

References
1.
Revicki D, Rentz A, Harnam N, Thomas V, Lanzetta P . Reliability and validity of the National Eye Institute Visual Function Questionnaire-25 in patients with age-related macular degeneration. Invest Ophthalmol Vis Sci. 2009; 51(2):712-7. DOI: 10.1167/iovs.09-3766. View

2.
Ferris 3rd F, Wilkinson C, Bird A, Chakravarthy U, Chew E, Csaky K . Clinical classification of age-related macular degeneration. Ophthalmology. 2013; 120(4):844-51. PMC: 11551519. DOI: 10.1016/j.ophtha.2012.10.036. View

3.
Mitchell J, Bradley C . Design of an individualised measure of the impact of macular disease on quality of life (the MacDQoL). Qual Life Res. 2004; 13(6):1163-75. DOI: 10.1023/B:QURE.0000031348.51292.4a. View

4.
Taylor J, Bambrick R, Brand A, Bray N, Dutton M, Harper R . Effectiveness of portable electronic and optical magnifiers for near vision activities in low vision: a randomised crossover trial. Ophthalmic Physiol Opt. 2017; 37(4):370-384. DOI: 10.1111/opo.12379. View

5.
Patnaik J, Lynch A, Pecen P, Jasso M, Hanson K, Mathias M . The impact of advanced age-related macular degeneration on the National Eye Institute's Visual Function Questionnaire-25. Acta Ophthalmol. 2020; 99(7):750-755. DOI: 10.1111/aos.14731. View